June 13, 2016
The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result...read more